The decision comes a few months after the first drug to be approved in the UK for alopecia – Eli Lilly ... and Chairman Fabrizio Chines about a new treatment for acanthamoeba keratitis.

A man suffering alopecia says he is being denied a groundbreaking new drug – despite it being approved. The daily pill, called ritlecitinib or Litfulo, was green-lit for prescription on the NHS ...

A woman with alopecia has welcomed approval for a new hair loss medicine on the NHS in Wales. "This is amazing news," said Brittany Hardaker, 26, who was diagnosed with alopecia when she was 12 ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

According to GlobalData, Phase II drugs for Alopecia Areata have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ...

The substantial data supporting platelet-rich plasma (PRP) therapy and exosomes for androgenic alopecia have yet to convince ...

Celiac disease is associated with an increased risk for developing alopecia areata, according to a letter to the editor published online in the Journal of the American Academy of Dermatology. Rashwan ...

The global alopecia treatment market size was valued at USD 3.48 billion in 2024 and is projected to reach from USD 3.62 billion in 2025 to USD 5.20 billion by 2033, growing at a CAGR of 4.1% during ...

Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart. The company said ...

LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire / -- The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.